Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
The Medicines Company, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
The Medicines Company, Medical Devices Deals, 2012 to YTD 2018 10
The Medicines Company, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
The Medicines Company, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Medicines Company Exercises Option to Acquire Recothrom from Bristol-Myers Squibb for USD132 Million 13
Venture Financing 14
Annovation BioPharma Raises US$8 Million In Series A Financing 14
Annovation BioPharma Raises US$2 Million In Venture Financing 15
Partnerships 16
The Medicines Company Enters into Agreement with BARDA 16
Medicines Company Enters into Distribution Agreement with Sandoz for Angiomax 17
Licensing Agreements 18
Medicines Company Enters into Licensing Agreement with SciClone 18
Medicines Company Enters Into Licensing Agreement With Bristol-Myers Squibb For Recothrom 20
Medicines Company Enters Into Licensing Agreement With Alnylam Pharma To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 22
Medicines Company Enters Into Licensing Agreement With APP For Acute Care Generic Products 24
Equity Offering 25
The Medicines Company Completes Public Offering Of Shares For US$201.3 Million 25
Debt Offering 26
The Medicines Company Raises USD402.5 Million in Private Placement of 2.75% Notes Due 2023 26
Medicines Company Raises USD400 million in Private Placement of 2.5% Notes Due 2022 28
The Medicines Company Completes Private Placement Of Notes For US$275 Million 29
Asset Transactions 30
Melinta Therapeutics Acquires Infectious Disease Business Unit from The Medicines Company 30
Chiesi Farmaceutici Acquires Cardiovascular Assets of The Medicines Company for up to USD743.8 Million 32
Mallinckrodt Acquires Three Topical Hemostasis Drugs from Medicines Company 34
Acquisition 36
Medicines Company Acquires Annovation Biopharma 36
Medicines Company Acquires Rempex Pharma For US$474 Million 37
Medicines Company Completes Acquisition Of ProFibrix For Up To US$240 Million 39
Medicines Company Completes Acquisition Of Incline Therapeutics For US$185 Million 41
The Medicines Company – Key Competitors 43
The Medicines Company – Key Employees 44
The Medicines Company – Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Recent Developments 47
Financial Announcements 47
Aug 01, 2018: The Medicines Company Reports Second-Quarter 2018 Results 47
Apr 25, 2018: The Medicines Company Reports First-Quarter 2018 Results 49
Feb 21, 2018: The Medicines Company Reports Fourth-Quarter and Full-Year 2017 Business and Financial Results 51
Oct 25, 2017: The Medicines Company Reports Third-Quarter 2017 Business and Financial Results 53
Aug 09, 2017: The Medicines Company Reports Second Quarter 2017 Business and Financial Results 55
Apr 26, 2017: The Medicines Company Reports First-Quarter 2017 Financial Results 57
Feb 28, 2017: The Medicines Company Reports Fourth-Quarter and Full-Year 2016 Financial Results 58
Corporate Communications 60
Mar 27, 2018: The Medicines Company Announces Chief Financial Officer Transition 60
Feb 27, 2018: The Medicines Company Appoints Dr. Sarah Schlesinger to Its Board of Directors 61
Nov 15, 2017: The Medicines Company Names Dr. Fred Eshelman as Executive Chairman; Appoints Geno Germano to Its Board of Directors 62
Mar 31, 2017: The Medicines Company Appoints Paris Panayiotopoulos to Its Board of Directors 63
Clinical Trials 64
Apr 26, 2017: The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical Program for Inclisiran 64
Mar 17, 2017: The Medicines Company and Alnylam Pharmaceuticals Report Positive Final Results from ORION-1 Phase II Study of Inclisiran 66
Mar 14, 2017: The Medicines Company to Webcast Presentation of ORION-1 Phase II Study of Inclisiran at ACC.17 68
Jan 25, 2017: The Medicines Company to Present Results from ORION-1 Phase 2 Study of Inclisiran at the American College of Cardiology’s 66th Annual Scientific Session 69
Jan 08, 2017: The Medicines Company Announces Positive Top-Line Results from Day 180 Interim Analysis in Ongoing ORION-1 Phase 2 Study of Inclisiran 70
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72
The Medicines Company, Pharmaceuticals & Healthcare, Key Facts, 2017 2
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
The Medicines Company, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
The Medicines Company, Deals By Therapy Area, 2012 to YTD 2018 9
The Medicines Company, Medical Devices Deals, 2012 to YTD 2018 10
The Medicines Company, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Medicines Company Exercises Option to Acquire Recothrom from Bristol-Myers Squibb for USD132 Million 13
Annovation BioPharma Raises US$8 Million In Series A Financing 14
Annovation BioPharma Raises US$2 Million In Venture Financing 15
The Medicines Company Enters into Agreement with BARDA 16
Medicines Company Enters into Distribution Agreement with Sandoz for Angiomax 17
Medicines Company Enters into Licensing Agreement with SciClone 18
Medicines Company Enters Into Licensing Agreement With Bristol-Myers Squibb For Recothrom 20
Medicines Company Enters Into Licensing Agreement With Alnylam Pharma To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 22
Medicines Company Enters Into Licensing Agreement With APP For Acute Care Generic Products 24
The Medicines Company Completes Public Offering Of Shares For US$201.3 Million 25
The Medicines Company Raises USD402.5 Million in Private Placement of 2.75% Notes Due 2023 26
Medicines Company Raises USD400 million in Private Placement of 2.5% Notes Due 2022 28
The Medicines Company Completes Private Placement Of Notes For US$275 Million 29
Melinta Therapeutics Acquires Infectious Disease Business Unit from The Medicines Company 30
Chiesi Farmaceutici Acquires Cardiovascular Assets of The Medicines Company for up to USD743.8 Million 32
Mallinckrodt Acquires Three Topical Hemostasis Drugs from Medicines Company 34
Medicines Company Acquires Annovation Biopharma 36
Medicines Company Acquires Rempex Pharma For US$474 Million 37
Medicines Company Completes Acquisition Of ProFibrix For Up To US$240 Million 39
Medicines Company Completes Acquisition Of Incline Therapeutics For US$185 Million 41
The Medicines Company, Key Competitors 43
The Medicines Company, Key Employees 44
The Medicines Company, Subsidiaries 45
List of Figures
The Medicines Company, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
The Medicines Company, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
The Medicines Company, Medical Devices Deals, 2012 to YTD 2018 10